Dimerix Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DXB.AX research report →
Price Chart
About the company
Dimerix Limited is an Australian biopharmaceutical firm dedicated to discovering and bringing to market innovative pharmaceutical solutions for medical conditions where existing treatments are insufficient. The company's leading therapeutic candidate, DMX-200, is currently undergoing extensive clinical evaluation, including two separate Phase 3 trials targeting respiratory complications linked to COVID-19. DMX-200 is also in a distinct Phase 3 clinical trial for focal segmental glomerulosclerosis (FSGS), a severe kidney disorder, and is being developed for the treatment of diabetic kidney disease.
- CEO
- Nina Webster
- IPO
- 1989
- Employees
- 15
- HQ
- Fitzroy, VIC, AU
Get TickerSpark's AI analysis on DXB.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $186.12M
- P/E
- -11.40
- PEG
- -0.44
- P/S
- 25.10
- P/B
- -110.69
- EV/EBITDA
- -3.66
- Div Yield
- 0.00%
- Gross Margin
- 71.46%
- Op Margin
- -548.07%
- Net Margin
- -219.94%
- ROE
- -278.87%
- ROIC
- -78.37%
Latest fiscal year · YoY change
- Revenue
- $1.25M+115.0%
- Gross Profit
- $1.25M+115.0%
- Op Income
- $-36,341,349
- Net Income
- $-13,251,722+22.4%
- EPS
- $-0.02+37.4%
- OCF Growth
- +657.6%
- FCF Growth
- +656.0%
- 52W High
- $0.67
- 52W Low
- $0.16
- 50D MA
- $0.25
- 200D MA
- $0.37
- Beta
- 0.33
- RSI (14)
- 65
- Avg Volume
- 2.33M
No earnings-call transcripts are available for DXB.AX yet.
- Free Float
- 78.4%
- Shares Outstanding
- 600.40M
- Float Shares
- 470.69M
Our DXB.AX coverage
Recent articles, reports, and earnings notes.
No research on DXB.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DXB.AX report →Dimerix licenses DMX-200 rights in Asia to Everest Medicines in deal worth up to A$481 million
proactiveinvestors.com · Jun 16
BLINDED ASSESSMENT OF ACTION3 STATISTICAL ASSUMPTIONS COMPLETE
prnewswire.com · Apr 28
Imugene highlights azer-cel progress as trial patient enters remission
proactiveinvestors.com · Mar 10
Dimerix completes adult dosing in ACTION3 Phase 3 trial as enrolment tops target
proactiveinvestors.com · Mar 10
Imugene reports strong early response rates for azer-cel in lymphoma study
proactiveinvestors.com · Mar 10
Pantoro posts stronger half-year result as Norseman production drives earnings
proactiveinvestors.com · Mar 10
Dimerix US licensing agreement remains intact amid BioMarin–Amicus acquisition
proactiveinvestors.com · Dec 22
DMX-200 ACTION3 PHASE 3 TRIAL COMPLETES RECRUITMENT
prnewswire.com · Dec 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.